NCT06804590View on ClinicalTrials.gov

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

November 16, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

July 30, 2026

Conditions
Postmenopausal Women Osteoporosis
Interventions
DRUG

9MW0311

9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

DRUG

Prolia®

Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Trial Locations (1)

Unknown

RECRUITING

Mabwell (Shanghai) Bioscience Co., Ltd., Beijing

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY